| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/01/2011 | CN102078596A Application of toad peptide antibiotics in preparing drugs for treating hemorrhoids |
| 06/01/2011 | CN102078595A Application of toad peptide antibiotic for preparing medicines for curing tinea manus and pedis |
| 06/01/2011 | CN102078594A Application of toad peptide antibiotics in preparing drugs for treating anal fistula |
| 06/01/2011 | CN102078593A Application of toad peptide antibiotic for preparing medicines for curing diabetic foot |
| 06/01/2011 | CN102078592A Application of toad peptide antibiotics in preparing drugs for treating acnes |
| 06/01/2011 | CN102078304A Insulin drug carried microspheres and preparation method thereof |
| 06/01/2011 | CN102078292A Collagen oral liquid with improved bioavailability |
| 06/01/2011 | CN102077928A Tilapia immune potentiator and preparation method thereof |
| 06/01/2011 | CN102077901A Swine hemoglobin enzymolysis and decoloration method |
| 06/01/2011 | CN101721376B Calcitonin sustained release microsphere composition and preparation method thereof |
| 06/01/2011 | CN101669905B Thymosin alpha1 injection-type subcutaneous implant |
| 06/01/2011 | CN101601659B Glutathione enteric-coated pellet and preparation method thereof |
| 06/01/2011 | CN101502489B Intestinal nutrient solution with special medical goal |
| 06/01/2011 | CN101348521B Aminoacid mimic epitope of human B lymphocyte stimulating factor receptor and use thereof |
| 06/01/2011 | CN101343328B Target-specificity dual-mutant amalgamation protein |
| 06/01/2011 | CN101336110B Peptide for preventing and treating liver harm, derivative and application thereof |
| 06/01/2011 | CN101323641B Anti-opioid peptide, antagonistic peptide thereof and use thereof |
| 06/01/2011 | CN101210046B Antifungal protein and usage thereof |
| 06/01/2011 | CN101099860B Use of erythropoietin |
| 05/31/2011 | US7951933 Adenosine triphophate-ribosylcyclase for identifying modulators to prevent and treat autoimmune, skin and inflammatory disorders |
| 05/31/2011 | US7951919 TACI-immunoglobulin fusion proteins |
| 05/31/2011 | US7951913 Method of polymyxin B recovery from fermentation broth |
| 05/31/2011 | US7951911 Carbon nanotube binding peptides |
| 05/31/2011 | US7951909 A polypeptide containing an N-terminal fragment of Amyloid beta (A beta ) peptide linked to a helper T cell epitope (Th) having multiple class II binding motifs; generated antibodies are highly cross-reactive to the soluble A beta 1-42 peptide and the amyloid plaques in the brain |
| 05/31/2011 | US7951908 Recombinant spider silk proteins |
| 05/31/2011 | US7951907 Circovirus sequences associated with piglet weight loss disease (PWD) |
| 05/31/2011 | US7951906 Compounds capable of interacting with a cell-surface fibroblast growth factor receptor |
| 05/31/2011 | US7951847 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 05/31/2011 | US7951793 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/31/2011 | US7951786 Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides |
| 05/31/2011 | US7951782 Composition effective to prevent or treat adult disease |
| 05/31/2011 | US7951781 Methods and compositions related to PLUNC surfactant polypeptides |
| 05/31/2011 | US7951780 Antitumor agent |
| 05/31/2011 | US7951779 Method of protecting cells against damage and pharmaceutical composition comprising leumorphin |
| 05/31/2011 | US7951778 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis |
| 05/31/2011 | US7951777 administering one or more of vasoactive intestinal peptide (VIP) and active fragment(s) fortherapeutic treatment of myocardial fibrosis or an associated condition in a patient |
| 05/31/2011 | US7951776 Methods for treatment of type 1 diabetes |
| 05/31/2011 | US7951775 Methods and pharmaceutical compositions for GnRH-I and GnRH-II modulation of T-cell activity, adhesion, migration and extravasation |
| 05/31/2011 | US7951774 Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment |
| 05/31/2011 | US7951773 Ring-closing metathesis process for the preparation of macrocyclic peptides |
| 05/31/2011 | US7951772 Tumor-activated prodrug compounds and treatment |
| 05/31/2011 | US7951771 Activin-ActRIIa antagonists and uses for promoting bone growth |
| 05/31/2011 | US7951770 Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process |
| 05/31/2011 | US7951614 Methods and compositions for the production of monoclonal antibodies |
| 05/31/2011 | US7951613 Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion |
| 05/31/2011 | US7951585 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof |
| 05/31/2011 | US7951560 Delta 4,5 glycuronidase compositions and methods related thereto |
| 05/31/2011 | US7951405 Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor |
| 05/31/2011 | US7951396 Preparation of nanoliposome-encapsulating proteins and protein-encapsulated nanoliposome |
| 05/31/2011 | US7951386 Recombinant cytochrome oxidase and/or morula membrane protein for use in developing therapeutics which prevent infection associated with mite parasitfes |
| 05/31/2011 | US7951382 Methods for treatment of type 2 diabetes |
| 05/31/2011 | US7951381 Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor |
| 05/31/2011 | US7951380 Methods of stimulating bone growth using ZVEGF4 polypeptides |
| 05/31/2011 | US7951378 Modified cell adhesion molecule comprising immunoglobulin heavy chain fusion for treatment and prevention of respiratory system disorders |
| 05/31/2011 | US7951376 Multimeric complexes of antigens and an adjuvant |
| 05/31/2011 | US7951375 Methods of inducing an immune response |
| 05/31/2011 | US7951373 Administering to mammal a neural growth and/or remyelination and/or neuroprotection promoting amount of an agent comprising a neural cell adhesion molecule, which molecule is capable of overcoming inhibitory molecular cues found on glial cells |
| 05/31/2011 | US7951372 Method of treating psoriasis by administering IL-22 antibodies, or binding fragments thereof |
| 05/31/2011 | US7951371 Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling |
| 05/31/2011 | US7951367 Using cathepsin variant as therapeutic tool in treatment and prevention of nervous system disorders |
| 05/31/2011 | US7951366 Recombinant human arginase functioning as arginine depleting agent in treatment of cell proliferative disorders |
| 05/31/2011 | US7951364 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| 05/31/2011 | US7951360 Mutant interleukin-2 (IL-2) polypeptides |
| 05/31/2011 | US7951359 Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy |
| 05/31/2011 | US7951356 Tissue factor compositions and kits for coagulation and tumor treatment |
| 05/31/2011 | CA2542449C Combined preparation for treating sepsis |
| 05/31/2011 | CA2521182C Composition for improving cognition and memory |
| 05/31/2011 | CA2441357C Agent for the prevention and treatment of sexually transmitted diseases-i |
| 05/31/2011 | CA2416566C Depot formulation comprising ceftiofur and peroxidized natural oil |
| 05/31/2011 | CA2400929C Antagonistic selective binding agents of osteoprotegerin binding protein |
| 05/31/2011 | CA2398929C Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc) |
| 05/31/2011 | CA2398539C Myeloid colony stimulating factor and uses thereof |
| 05/31/2011 | CA2319080C Multivalent antibacterial agents |
| 05/31/2011 | CA2231772C Advanced glycation end-product intermediaries and post-amadori inhibition |
| 05/31/2011 | CA2215328C Novel human cytomegalovirus dna sequences |
| 05/26/2011 | WO2011063419A2 Lipopeptide compositions and related methods |
| 05/26/2011 | WO2011063414A1 Polypeptide conjugate |
| 05/26/2011 | WO2011063394A2 Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions |
| 05/26/2011 | WO2011063336A2 Secondary site of antigen stimulation for therapeutic vaccination |
| 05/26/2011 | WO2011063320A2 Recombinant filaggrin polypeptides for cell importation |
| 05/26/2011 | WO2011063275A1 Suppression of cancer metastasis |
| 05/26/2011 | WO2011063263A2 Methods for producing an immune response to tuberculosis |
| 05/26/2011 | WO2011063161A2 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr) |
| 05/26/2011 | WO2011063160A1 Methods for improving oral delivery |
| 05/26/2011 | WO2011063152A1 Methods and compositions for soft tissue repair |
| 05/26/2011 | WO2011063133A1 LOW ANTIGEN-DOSE IMMUNIZATION FOR MAXIMIZING T-HELPER CELL 1 (T h1) IMMUNITY AGAINST DISEASE |
| 05/26/2011 | WO2011063090A2 Peptide protection against ultraviolet light toxicity |
| 05/26/2011 | WO2011063048A2 Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| 05/26/2011 | WO2011063018A1 Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| 05/26/2011 | WO2011062786A2 Compounds and methods for inhibiting the metastasis of cancer cells |
| 05/26/2011 | WO2011062762A2 Angiogenin and variants thereof for treatment of neurodegenerative diseases |
| 05/26/2011 | WO2011062676A1 Formulations of daptomycin |
| 05/26/2011 | WO2011062147A1 Method for inducing differentiation of dental pulp cells into odontoblasts |
| 05/26/2011 | WO2011062073A1 Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
| 05/26/2011 | WO2011061736A1 Alkaline alpha galactosidase for the treatment of fabry disease |
| 05/26/2011 | WO2011061615A1 Polysaccharide / bmp complexes which are soluble at physiological ph |
| 05/26/2011 | WO2011061236A1 Pharmaceutical compositions comprising an lrp1 receptor agonist for the treatment of cancer and hiv |
| 05/26/2011 | WO2011060937A1 Template-fixed peptidomimetics with ccr10 antagonistic activty |
| 05/26/2011 | WO2011060922A1 Formulation for hgh and rhigf-1 combination |
| 05/26/2011 | WO2011060832A1 Template-fixed peptidomimetics with ccr10 antagonistic activity |